Summary of INmune Bio Conference Call on February 26, 2026 Company and Industry Overview - **Company**: INmune Bio (NasdaqCM:INMB) - **Industry**: Cellular therapy, specifically targeting Recessive Dystrophic Epidermolysis Bullosa (RDEB) Key Points and Arguments Clinical Trial Updates - **Mission EB Phase III Clinical Trial**: Focused on CORDStrom for treating RDEB, a severe skin condition characterized by fragile skin and blistering [1][2] - **CORDStrom**: A pooled umbilical cord-derived mesenchymal stromal cell product, showing promise as a disease-modifying therapy for RDEB [4][5] - **Trial Results**: - 30 patients completed the trial with no serious adverse events reported [14] - Significant reductions in itch: 21% at 3 months and 26% at 6 months [15] - Pain reduction: Average pain improved by 22% and worst pain by 28% [16] - Sustained improvements in skin scores observed at 6 months [17] Mechanism of Action - **CORDStrom's Mechanism**: Suppresses inflammation, enhances wound healing, and potentially reduces fibrosis [5][27] - **Cytokine Release**: CORDStrom secretes various cytokines that may facilitate the transition from pro-inflammatory M1 macrophages to anti-inflammatory M2 macrophages, promoting healing [36][42] Market Opportunity - **Current Treatments**: Existing treatments like Filsuvez and Vyjuvek are limited in effectiveness and accessibility, highlighting the urgent need for systemic anti-inflammatory therapies [10][11][12] - **Commercialization Path**: INmune Bio is preparing for market entry with plans for regulatory submissions and scaling up production [44][45][48] Future Directions - **Open Label Study**: A new study, Mission EB Deliver, will treat all children who participated in the trial, with plans for ongoing data collection [22] - **Potential for Other EB Types**: Discussions are ongoing about the applicability of CORDStrom for other types of EB, such as junctional EB [65][75] Additional Important Information - **Patient Feedback**: Qualitative data from parents and children indicate significant improvements in quality of life, with many reporting less pain and better overall well-being [19][20][21] - **Regulatory Engagement**: Continuous communication with regulatory bodies like the FDA and MHRA to ensure compliance and facilitate approval processes [45][46] - **Combination Therapy Potential**: CORDStrom is seen as a critical component of a broader treatment strategy for EB, potentially used alongside other therapies [72][74] This summary encapsulates the pivotal updates and insights shared during the conference call, emphasizing the potential impact of CORDStrom on the treatment landscape for RDEB and the company's strategic direction moving forward.